The 8th Annual Translational Microbiome Conference

This conference will bring together the leading microbiome companies working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond. Expanding on this core focus year on year, we continue to offer panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond the usual infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.

Entering its 8th year in 2023, the meeting will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear the leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health and improved outcomes.

Speakers: Chrysi Sergaki, Ph.D., Principal Investigator, Microbiome Group Group Leader Medicines and Healthcare Products Regulatory Agency, United Kingdom, Matt Amicucci, Ph.D., Co-Founder, VP of Research and Development, BCD Bio, Guru Banavar, Ph.D., Chief Technology Officer, Head of Discovery, Viome, Chris Damman, MD, Clinical Associate Professor, University of Washington, Hasan Nur, Ph.D., MBA, Chief Executive Officer, EZ Biome, Jacques Ravel, Ph.D., Chief Scientist/Associate Director for Genomics, LUCA Biologics/Institute for Genome Sciences, University of Maryland School of Medicine, Jay Tiesman, Ph.D., Research Fellow, Genomics Group Leader, Procter and Gamble